Regeneron to Pay $40M Upfront in Telix Radiopharma Deal, $2.1B Milestones
Regeneron will pay $40 million upfront to Telix Pharmaceuticals for its radiopharmaceutical platform, partnering to co-develop up to eight solid tumour therapies with equal cost and profit sharing. The collaboration includes options for four more programmes and potential milestone payments up to $2.1 billion plus low double-digit royalties.
1. Collaboration Scope
Regeneron and Telix Pharmaceuticals have entered a collaboration to co-develop radiopharmaceutical therapies targeting solid tumours. Under the agreement, Regeneron gains access to Telix’s manufacturing platform for four initial therapeutic programmes, with an option to expand to four additional initiatives.
2. Financial Terms
Regeneron will provide a $40 million upfront payment and equally share development costs and global profits with Telix. The deal offers up to $2.1 billion in development and commercial milestone payments, plus low double-digit royalties on net sales.
3. Programme Expansion Options
The agreement allows Regeneron to trigger four extra programmes through additional upfront payments. If Telix opts out of funding a specific programme, it becomes eligible for milestone payments and royalties, preserving its upside.
4. Strategic Impact
This collaboration integrates Telix’s radiopharmaceutical expertise with Regeneron’s biologics and bispecific antibody capabilities, aiming to broaden Regeneron’s precision oncology portfolio and accelerate novel treatment modalities for solid tumour patients.